vs
EXACT SCIENCES CORP（EXAS）与Cloudflare, Inc.（NET）财务数据对比。点击上方公司名可切换其他公司
EXACT SCIENCES CORP的季度营收约是Cloudflare, Inc.的1.4倍（$878.4M vs $614.5M），Cloudflare, Inc.净利率更高（-2.0% vs -9.8%，领先7.8%），Cloudflare, Inc.同比增速更快（33.6% vs 23.1%），EXACT SCIENCES CORP自由现金流更多（$120.4M vs $105.2M），过去两年Cloudflare, Inc.的营收复合增速更高（27.4% vs 17.4%）
Exact Sciences是总部位于美国威斯康星州麦迪逊的分子诊断企业，专注于早期癌症检测领域。公司核心产品覆盖结直肠癌筛查与预防场景，其中Cologuard是全球首个获批的结直肠癌粪便DNA检测产品，同时还提供其他多种癌症的筛查服务及精准肿瘤检测解决方案。
Cloudflare是总部位于美国加利福尼亚州旧金山的科技企业，提供内容分发网络（CDN）、云网络安全、DDoS防护等多元互联网服务，同时是ICANN认证的域名注册商。其服务作为网站访客与客户托管服务商之间的反向代理，可有效提升访问性能，抵御恶意流量。
EXAS vs NET — 直观对比
营收规模更大
EXAS
是对方的1.4倍
$614.5M
营收增速更快
NET
高出10.5%
23.1%
净利率更高
NET
高出7.8%
-9.8%
自由现金流更多
EXAS
多$15.2M
$105.2M
两年增速更快
NET
近两年复合增速
17.4%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $878.4M | $614.5M |
| 净利润 | $-86.0M | $-12.1M |
| 毛利率 | 70.1% | 73.6% |
| 营业利润率 | -9.4% | -8.0% |
| 净利率 | -9.8% | -2.0% |
| 营收同比 | 23.1% | 33.6% |
| 净利润同比 | 90.1% | 6.0% |
| 每股收益（稀释后） | $-0.45 | $-0.03 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EXASNET
| Q4 25 | $878.4M | $614.5M | ||
| Q3 25 | $850.7M | $562.0M | ||
| Q2 25 | $811.1M | $512.3M | ||
| Q1 25 | $706.8M | $479.1M | ||
| Q4 24 | $713.4M | $459.9M | ||
| Q3 24 | $708.7M | $430.1M | ||
| Q2 24 | $699.3M | $401.0M | ||
| Q1 24 | $637.5M | $378.6M |
净利润EXASNET
| Q4 25 | $-86.0M | $-12.1M | ||
| Q3 25 | $-19.6M | $-1.3M | ||
| Q2 25 | $-1.2M | $-50.4M | ||
| Q1 25 | $-101.2M | $-38.5M | ||
| Q4 24 | $-864.6M | $-12.8M | ||
| Q3 24 | $-38.2M | $-15.3M | ||
| Q2 24 | $-15.8M | $-15.1M | ||
| Q1 24 | $-110.2M | $-35.5M |
毛利率EXASNET
| Q4 25 | 70.1% | 73.6% | ||
| Q3 25 | 68.6% | 74.0% | ||
| Q2 25 | 69.3% | 74.9% | ||
| Q1 25 | 70.8% | 75.9% | ||
| Q4 24 | 69.0% | 76.4% | ||
| Q3 24 | 69.4% | 77.7% | ||
| Q2 24 | 69.8% | 77.8% | ||
| Q1 24 | 70.0% | 77.5% |
营业利润率EXASNET
| Q4 25 | -9.4% | -8.0% | ||
| Q3 25 | -3.0% | -6.7% | ||
| Q2 25 | -0.3% | -13.1% | ||
| Q1 25 | -13.6% | -11.1% | ||
| Q4 24 | -122.8% | -7.5% | ||
| Q3 24 | -5.6% | -7.2% | ||
| Q2 24 | -3.8% | -8.7% | ||
| Q1 24 | -16.7% | -14.4% |
净利率EXASNET
| Q4 25 | -9.8% | -2.0% | ||
| Q3 25 | -2.3% | -0.2% | ||
| Q2 25 | -0.1% | -9.8% | ||
| Q1 25 | -14.3% | -8.0% | ||
| Q4 24 | -121.2% | -2.8% | ||
| Q3 24 | -5.4% | -3.6% | ||
| Q2 24 | -2.3% | -3.8% | ||
| Q1 24 | -17.3% | -9.4% |
每股收益（稀释后）EXASNET
| Q4 25 | $-0.45 | $-0.03 | ||
| Q3 25 | $-0.10 | $0.00 | ||
| Q2 25 | $-0.01 | $-0.15 | ||
| Q1 25 | $-0.54 | $-0.11 | ||
| Q4 24 | $-4.69 | $-0.05 | ||
| Q3 24 | $-0.21 | $-0.04 | ||
| Q2 24 | $-0.09 | $-0.04 | ||
| Q1 24 | $-0.60 | $-0.10 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $964.7M | $943.5M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $2.4B | $1.5B |
| 总资产 | $5.9B | $6.0B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资EXASNET
| Q4 25 | $964.7M | $943.5M | ||
| Q3 25 | $1.0B | $1.1B | ||
| Q2 25 | $858.4M | $1.5B | ||
| Q1 25 | $786.2M | $204.5M | ||
| Q4 24 | $1.0B | $147.7M | ||
| Q3 24 | $1.0B | $182.9M | ||
| Q2 24 | $946.8M | $157.0M | ||
| Q1 24 | $652.1M | $254.4M |
股东权益EXASNET
| Q4 25 | $2.4B | $1.5B | ||
| Q3 25 | $2.5B | $1.3B | ||
| Q2 25 | $2.5B | $1.2B | ||
| Q1 25 | $2.4B | $1.4B | ||
| Q4 24 | $2.4B | $1.0B | ||
| Q3 24 | $3.2B | $973.1M | ||
| Q2 24 | $3.2B | $881.5M | ||
| Q1 24 | $3.1B | $797.2M |
总资产EXASNET
| Q4 25 | $5.9B | $6.0B | ||
| Q3 25 | $5.9B | $5.8B | ||
| Q2 25 | $5.8B | $5.6B | ||
| Q1 25 | $5.7B | $3.7B | ||
| Q4 24 | $5.9B | $3.3B | ||
| Q3 24 | $6.7B | $3.1B | ||
| Q2 24 | $6.7B | $2.9B | ||
| Q1 24 | $6.4B | $2.8B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $151.7M | $190.4M |
| 自由现金流经营现金流 - 资本支出 | $120.4M | $105.2M |
| 自由现金流率自由现金流/营收 | 13.7% | 17.1% |
| 资本支出强度资本支出/营收 | 3.6% | 13.9% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $356.8M | $287.5M |
8季度趋势，按日历期对齐
经营现金流EXASNET
| Q4 25 | $151.7M | $190.4M | ||
| Q3 25 | $219.9M | $167.1M | ||
| Q2 25 | $89.0M | $99.8M | ||
| Q1 25 | $30.8M | $145.8M | ||
| Q4 24 | $47.1M | $127.3M | ||
| Q3 24 | $138.7M | $104.7M | ||
| Q2 24 | $107.1M | $74.8M | ||
| Q1 24 | $-82.3M | $73.6M |
自由现金流EXASNET
| Q4 25 | $120.4M | $105.2M | ||
| Q3 25 | $190.0M | $82.5M | ||
| Q2 25 | $46.7M | $39.9M | ||
| Q1 25 | $-365.0K | $59.9M | ||
| Q4 24 | $10.7M | $54.2M | ||
| Q3 24 | $112.6M | $54.5M | ||
| Q2 24 | $71.2M | $45.2M | ||
| Q1 24 | $-120.0M | $41.5M |
自由现金流率EXASNET
| Q4 25 | 13.7% | 17.1% | ||
| Q3 25 | 22.3% | 14.7% | ||
| Q2 25 | 5.8% | 7.8% | ||
| Q1 25 | -0.1% | 12.5% | ||
| Q4 24 | 1.5% | 11.8% | ||
| Q3 24 | 15.9% | 12.7% | ||
| Q2 24 | 10.2% | 11.3% | ||
| Q1 24 | -18.8% | 11.0% |
资本支出强度EXASNET
| Q4 25 | 3.6% | 13.9% | ||
| Q3 25 | 3.5% | 15.1% | ||
| Q2 25 | 5.2% | 11.7% | ||
| Q1 25 | 4.4% | 17.9% | ||
| Q4 24 | 5.1% | 15.9% | ||
| Q3 24 | 3.7% | 11.7% | ||
| Q2 24 | 5.1% | 7.4% | ||
| Q1 24 | 5.9% | 8.5% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EXAS
| Screening | $695.1M | 79% |
| Precision Oncology | $183.2M | 21% |
NET
| Sales Channel Directly To Consumer | $438.5M | 71% |
| Sales Channel Through Intermediary | $176.0M | 29% |
